Literature DB >> 28161735

Development of a Report Card for Identifying Local Sublingual Immunotherapy Events in Clinical Trials.

Josephine Norquist1, Emuella Flood2, Tiffany Tanzosh3, Haojie Li3, Beata Iskold3, Thelma Rose Ganser2, Helen Marson-Smith2.   

Abstract

BACKGROUND: The sublingual immunotherapy (SLIT) Report Card was developed to capture patient-reported local reactions from the administration of SLIT, based on the World Allergy Organization side-effect grading system. The objective was to evaluate understandability, usability, and translatability of the paper and electronic versions of the SLIT Report Card.
METHODS: Adults (aged 18+ years), adolescents (aged 12-17 years), and parents/caregivers and their children (aged 5-11 years) participated in two rounds of interviews, testing the paper version in Round 1, and both the paper and electronic versions in Round 2. Interviews assessed comprehension and usability by subjects. Translatability identified potential issues related to translation or cultural relevance.
RESULTS: Ten adults, ten adolescents, and ten parent/child dyads were interviewed. In general, subjects demonstrated a clear understanding of the instrument's content. However, some subjects were uncertain of or suggested clarifying the meaning of certain terms, including tablet, ulcer, taste alteration, uvula, nausea, and itching in the ear. The translatability assessment also identified uvula and nausea as potentially problematic for translation. Subjects could use the electronic device and found navigation 'easy', with only a few minor suggestions made to improve usability. Some wording and formatting changes were made based on subjects' feedback and the translatability assessment.
CONCLUSION: The SLIT Report Card was refined following best practices for instrument development, including cognitive interviewing, usability, and translatability assessment. The refined SLIT Report Card is appropriate for comprehensively and systematically collecting SLIT-related local reactions directly from subjects in a clinical trial setting, taking into account the World Allergy Organization grading system.

Entities:  

Mesh:

Year:  2017        PMID: 28161735     DOI: 10.1007/s40271-017-0217-0

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  6 in total

1.  Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.

Authors:  Louis S Matza; Donald L Patrick; Anne W Riley; John J Alexander; Luis Rajmil; Andreas M Pleil; Monika Bullinger
Journal:  Value Health       Date:  2013-06       Impact factor: 5.725

2.  Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006.

Authors:  Päivi M Salo; Samuel J Arbes; Renee Jaramillo; Agustin Calatroni; Charles H Weir; Michelle L Sever; Jane A Hoppin; Kathryn M Rose; Andrew H Liu; Peter J Gergen; Herman E Mitchell; Darryl C Zeldin
Journal:  J Allergy Clin Immunol       Date:  2014-02-09       Impact factor: 10.793

3.  Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.

Authors:  Stephen Joel Coons; Chad J Gwaltney; Ron D Hays; J Jason Lundy; Jeff A Sloan; Dennis A Revicki; William R Lenderking; David Cella; Ethan Basch
Journal:  Value Health       Date:  2008-11-11       Impact factor: 5.725

4.  Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language.

Authors:  Giovanni Passalacqua; Carlos E Baena-Cagnani; Jean Bousquet; Giorgio Walter Canonica; Thomas B Casale; Linda Cox; Stephen R Durham; Desiréé Larenas-Linnemann; Dennis Ledford; Ruby Pawankar; Paul Potter; Nelson Rosario; Dana Wallace; Richard F Lockey
Journal:  J Allergy Clin Immunol       Date:  2013-05-15       Impact factor: 10.793

5.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Authors:  Giorgio Walter Canonica; Linda Cox; Ruby Pawankar; Carlos E Baena-Cagnani; Michael Blaiss; Sergio Bonini; Jean Bousquet; Moises Calderón; Enrico Compalati; Stephen R Durham; Roy Gerth van Wijk; Désirée Larenas-Linnemann; Harold Nelson; Giovanni Passalacqua; Oliver Pfaar; Nelson Rosário; Dermot Ryan; Lanny Rosenwasser; Peter Schmid-Grendelmeier; Gianenrico Senna; Erkka Valovirta; Hugo Van Bever; Pakit Vichyanond; Ulrich Wahn; Osman Yusuf
Journal:  World Allergy Organ J       Date:  2014-03-28       Impact factor: 4.084

Review 6.  Recommendations for appropriate sublingual immunotherapy clinical trials.

Authors:  Giovanni Passalacqua
Journal:  World Allergy Organ J       Date:  2014-10-06       Impact factor: 4.084

  6 in total
  1 in total

1.  Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis.

Authors:  Anne K Ellis; Remi Gagnon; David I Bernstein; Hendrik Nolte
Journal:  Allergy Asthma Clin Immunol       Date:  2021-12-09       Impact factor: 3.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.